Literature DB >> 28355948

Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer.

Wolfram Bohle1, Ruben Zachmann1, Wolfram G Zoller1.   

Abstract

BACKGROUND: The accuracy of endosonographic tumor staging after neoadjuvant therapy is less reliable than in primary staging. Therefore, the value of sequential endosonographic examinations after neaodjuvant chemotherapy in gastro-esophageal cancer is discussed controversially. Previous data suggest, that endoscopic ultrasound (EUS) after neoadjuvant treatment using other variables than classic uTN-criteria may identify patients with a better prognosis.
METHODS: In 67 patients with locally advanced gastric cancer treated in curative intent, we performed EUS before and after neoadjuvant chemotherapy. Endosonographic yTN-stage was compared to pathohistological yTN-stage after curative resection. The uTN-stage, yuTN-stage, maximal tumor thickness and maximal lymph node diameter as well as the shift of these variables after neoadjuvant therapy were analyzed for their usefulness to predict recurrence-free follow-up.
RESULTS: Accuracy of EUS for yTN-staging after neoadjuvant therapy was poor, especially in lower tumor stages. However, three heavily correlated variables analyzed by sequential EUS could be used for the prediction of prognosis: low endosonographic tumor stage (yuT0-2) after neoadjuvant chemotherapy, a decrease of two or more steps in uT-stage and a maximal tumor thickness of <15 mm after chemotherapy were significantly associated with recurrence-free follow-up. Endosonographic T-stage before neoadjuvant therapy, as well as lymph node variables before or after chemotherapy, were of no predictive value.
CONCLUSION: In spite of poor concordance between endosonographic and pathohistological TN-stage after neoadjuvant treatment, sequential EUS, performed before and after neoadjuvant therapy, possibly identify patients at risk for tumor relapse after multimodal treatment in gastric cancer. This finding should be validated in a larger patient cohort.

Entities:  

Keywords:  Endoscopic ultrasound; gastric cancer; neoadjuvant therapy; prognosis; tumor staging

Mesh:

Year:  2017        PMID: 28355948     DOI: 10.1080/00365521.2017.1303845

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  2 in total

1.  Preoperative EUS evaluation of the response to neoadjuvant therapy for gastric and esophagogastric junction cancer is correlated with survival: A single retrospective study of 97 patients.

Authors:  Solène Hoibian; Marc Giovannini; Aurélie Autret; Christian Pesenti; Erwan Bories; Jean-Philippe Ratone; Yanis Dahel; Slimane Dermeche; Hélène Meillat; Jérôme Guiramand; Fabrice Caillol
Journal:  Endosc Ultrasound       Date:  2021 Mar-Apr       Impact factor: 5.628

Review 2.  Diagnostic Value of Endoscopic Ultrasound after Neoadjuvant Chemotherapy for Gastric Cancer Restaging: A Meta-Analysis of Diagnostic Test.

Authors:  Victor Mihai Sacerdotianu; Bogdan Silviu Ungureanu; Sevastita Iordache; Adina Turcu-Stiolica; Antonio Facciorusso; Stefano Francesco Crinò; Adrian Saftoiu
Journal:  Diagnostics (Basel)       Date:  2022-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.